Authored by James Sheppard
At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Jeff Leiden performed for Vertex in 2013.
2013 Liftstream Analysis: 2012 was a tumultuous year for Vertex with a number positive trials reporting, however this was partly overshadowed by cystic fibrosis data issue in the summer. However, Vertex’s Cystic Fibrosis drug, Kalydeco was one of the most important drug approvals in 2012 and looks set to help Vertex dominate the cystic fibrosis market.
• Ensure continued investor faith in Vertex Pharmaceuticals
• Ensure Vertex seals its commercial position in the Cystic Fibrosis market with Kalydeco
• Drive forward attempts to expand Kalydeco’s use by combining it with other drugs
2014 Liftstream Verdict: Good year, bad year is the consensus view of Vertex’s 2013. From an investor perspective shares have continued to trade towards their 52 week high of $89.96. It has been doing a good job in commercialising the product Kalydeco in cystic fibrosis. Expanding its use through other trials has led to a failed trail in December though. The company also decided to pull away from Hepatitis C with new therapies like Gilead’s Solvadi coming to market. Jeff Leiden decided the Hep C market was becoming too crowded and offloaded its Hep C product INCIVEK for $152m to Janssen. The rationale behind this was that Vertex wants to concentrate more on its Cystic Fibrosis franchise and other drugs in the pipeline, including oncology. This decision caused headcount reduction in Boston.
To see how the other leaders profiled in Liftstream’s 13 for 2013 performed please click here. Liftstream would very much like to hear your thoughts on how you believe these life science leaders performed in 2013. Please leave your comments below, email firstname.lastname@example.org or tweet @liftstream #LSL13for13
Liftstream is an executive search and interim management recruitment company working exclusively within the global life sciences sector.